Literature DB >> 20713100

TLR-based immune adjuvants.

Folkert Steinhagen1, Takeshi Kinjo, Christian Bode, Dennis M Klinman.   

Abstract

This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20713100      PMCID： PMC3000864          DOI： 10.1016/j.vaccine.2010.08.002

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  259 in total

1.  Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Authors:  Paul A Goepfert; Georgia D Tomaras; Helen Horton; David Montefiori; Guido Ferrari; Mark Deers; Gerald Voss; Marguerite Koutsoukos; Louise Pedneault; Pierre Vandepapeliere; M Juliana McElrath; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Lindsey R Baden; Clayton Harro; Thomas Evans
Journal:  Vaccine       Date:  2006-08-10       Impact factor: 3.641

2.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

3.  Inhibition of biologic activity of poly I: poly C by human plasma.

Authors:  J J Nordlund; S M Wolff; H B Levy
Journal:  Proc Soc Exp Biol Med       Date:  1970-02

4.  Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.

Authors:  B J Giantonio; H Hochster; R Blum; P H Wiernik; G R Hudes; J Kirkwood; D Trump; M M Oken
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

5.  Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.

Authors:  James W Huleatt; Andrea R Jacobs; Jie Tang; Priyanka Desai; Elizabeth B Kopp; Yan Huang; Langzhou Song; Valerian Nakaar; T J Powell
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

6.  Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

Authors:  Jeffrey A Sosman; Joseph M Unger; P-Y Liu; Lawrence E Flaherty; Min S Park; Raymond A Kempf; John A Thompson; Paul I Terasaki; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

7.  The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.

Authors:  Boubacar Traore; Younoussou Koné; Safiatou Doumbo; Didier Doumtabé; Abdramane Traoré; Peter D Crompton; Marko Mircetic; Chiung-Yu Huang; Kassoum Kayentao; Alassane Dicko; Issaka Sagara; Ruth D Ellis; Kazutoyo Miura; Agnes Guindo; Louis H Miller; Ogobara K Doumbo; Susan K Pierce
Journal:  Vaccine       Date:  2009-08-25       Impact factor: 3.641

8.  CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Authors:  W Nicholas Haining; Jeffrey Davies; Holger Kanzler; Linda Drury; Thomas Brenn; John Evans; Jill Angelosanto; Steven Rivoli; Kate Russell; Suzanne George; Paul Sims; Donna Neuberg; Xiaochun Li; Jeffrey Kutok; Jeffrey Morgan; Patrick Wen; George Demetri; Robert L Coffman; Lee M Nadler
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

Review 9.  TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity.

Authors:  Ulrich Zähringer; Buko Lindner; Seiichi Inamura; Holger Heine; Christian Alexander
Journal:  Immunobiology       Date:  2008-03-28       Impact factor: 3.144

10.  Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.

Authors:  Gregory A Prince; James J Mond; David D Porter; Kevin C Yim; Steve J Lan; Dennis M Klinman
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103
View more
  168 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Big thinking for adjuvants.

Authors:  Eric L Dane; Darrell J Irvine
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

3.  TLR vaccine adjuvants: closing the stable door before novel influenza strains bolt?

Authors:  Tracy Hussell; Anu Goenka
Journal:  Immunol Cell Biol       Date:  2015-11-17       Impact factor: 5.126

4.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

5.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

6.  Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.

Authors:  Rui Kuai; Xiaoqi Sun; Wenmin Yuan; Lukasz J Ochyl; Yao Xu; Alireza Hassani Najafabadi; Lindsay Scheetz; Min-Zhi Yu; Ishina Balwani; Anna Schwendeman; James J Moon
Journal:  J Control Release       Date:  2018-04-25       Impact factor: 9.776

7.  Effects of skeletal unloading on the bone marrow antibody repertoire of tetanus toxoid and/or CpG treated C57BL/6J mice.

Authors:  Trisha A Rettig; Nina C Nishiyama; Michael J Pecaut; Stephen K Chapes
Journal:  Life Sci Space Res (Amst)       Date:  2019-06-14

8.  The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells.

Authors:  Simone Schüller; Lukas Wisgrill; Kambis Sadeghi; Erich Gindl; Hanns Helmer; Peter Husslein; Angelika Berger; Andreas Spittler; Elisabeth Förster-Waldl
Journal:  Pediatr Res       Date:  2016-04-08       Impact factor: 3.756

9.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.

Authors:  Nicholas M Molino; Amanda K L Anderson; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Nano       Date:  2013-10-09       Impact factor: 15.881

10.  The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Evan Frazier; Reece Hoerle; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2016-08-18       Impact factor: 12.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.